This page provides brief summaries about new prostate cancer treatment that is either available now or is in development.
It will be updated regularly, so check back to find out what’s being touted as the latest treatment on prostate cancer blogs, drug and device manufacturer web sites, government, and other institutional web sites.
Also check our Today's Headlines section for more new developments.
March 13, 2014: Scientists at UT Southwestern Medical Center have identified an enzyme called USP9X that can potentially shut down the growth of prostate cancer cells, which may help men with metastatic prostate cancer.
December 3, 2013: Researchers at Texas Woman's University have shown in laboratory testing that a substance called diterpene geranylgeraniol, which is found in linseed oil, Cedrela toona wood oil, sucupira branca fruit oil, and annatto seed oil, can suppress certain prostate cancer cells.
December 1, 2013: The investigational oral drug tasquinimod has been shown to improve long-term survival by several months for men with metastatic castration-resistant prostate cancer (cancer that does not respond to hormonal therapy).
August 19, 2013: A key transcription factor (a protein that regulates the flow of information from DNA and is over-produced in prostate cancer that is resistent to treatment) and two protein kinases that trigger this process have been identified by researchers at Robert Wood Johnson Medical School who are studying the underlying mechanisms that cause invasive prostate cancer tumor growth.
August 7, 2013: Scientists at the University of Texas MD Anderson have identified a compound that blocks Skp2, a protein that can turn off a cellular defense against cancer.
August 1, 2013: Researchers at Sanford-Burnham Medical Institute have found a promising anticancer compound called SMIP004 that specifically kills prostate cancer cells by compromising their ability to withstand environmental stress.
May 15, 2013: The U.S. Food and Drug Administration has approved Xofigo® (radium 223 dichloride), a new prostate cancer treatment for men with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.
March 19, 2013: A shiitake mushroom-soybean extract is being studied by researchers at University of California-Davis and other centers as a potential treatment for prostate cancer.
March 18, 2013: Researchers have discovered that the protein Siah2 keeps a part of androgen receptors active constantly, which causes prostate cancer cells to resist treatment. It may be an important biomarkers for tracking a man's response to therapy and shows promise as a new method for resensitizing castration-resistant prostate cancer cells to hormone therapy.
February 25, 2013: A recombinant Newcastle disease virus has been shown to kill prostate cancer cells (including hormone-resistant cells) while leaving normal cells undamaged. Newcastle disease virus kills chickens and is being tested in several human studies.
August 30, 2012: Six medical centers in the US are participating in a clinical trial to evaluate Radium-223, an alpha-emitter for treating men with castration-resistant prostate cancer who have bone metastases. European studies have demonstrated that the drug increased survival by five months.
July 26, 2012: A new study that has been published in the Journal of Clinical Investigation reports that University of Rochester Medical Center scientists have discovered that a protein called paxillin is a key factor in prostate cancer. It is hoped that this news will lead to the development of a new prostate cancer treatment for men whose cancer cannot be cured, despite aggressive treatment efforts.
July 19, 2012: University of Missouri scientists have discovered a way to target and destroy prostate cancer tumors in mice with radioactive gold nano particles and a special compound found in tea leaves. This new prostate cancer treatment would be given in doses that are thousands of times lower than doses of chemotherapy that are being used to treat men with advanced prostate cancer, which can also kill healthy tissues. The next step is more animal studies and then human studies.
July 11, 2012: GenSpera, Inc. has announced pre-clinical data and rationale for the development of G-202 as a potential treatment for a variety of solid tumors (based on mice models). It also has validated the enzyme PSMA, which is expressed by prostate cancer cells, as a target for G-202. The next step will be a human clinical study.
May 5, 2012: University of Chicago researchers have disvovered that a compound made in honeybee hives appears to stop the spread of prostate cancer cells in mice, according to an ABC news report. This compound, which is called caffeic acid phenethyl ester (or CAPE), is made from propolis, which is resin that honeybees use to patch holes in their hives.
May 3, 2012: Carvacrol, a component of oregano, has caused prostate cancer cells to "commit suicide" in laboratory testing (called apoptosis), according to a Fox News Report.
February 1, 2012: A new radiopharmaceutical (I-131-MIP-1466) that is designed to deliver a therapeutic dose of radiation directly to metastatic prostate cancer, is expected to tested in clinical trials in early 2013. It will be the first trial of a small-molecule-based radiopharmaceutical specifically targeting prostate-specific membrane antigen (PSMA), a type of protein expressed in high levels on prostate tumors.
January 31, 2012: Scientists at Trinity College have developed a new vaccine to treat cancer at the pre-clinical level. This new prostate cancer treatment is based on manipulating the immune response to malignant tumors. The next step is to develop the vaccine for clinical use.
January 31, 2012: Dutasteride, which is commonly used to treat prostate enlargement, may also reduce the need for treatments that pose risks of incontinence and impotence — and delay growth of early-stage prostate cancer — according to a study published online first in The Lancet.
January 25, 2012: Researchers from Massachusetts Institute of Technology (MIT) and Massachusetts General Hospital have created a new drug delivery system that delivers chemotherapeutic drugs to prostate cancer cells.
September 15, 2011: Oncothyreon Inc. announced enrollment of the first patient in a Phase 2 trial of PX-866 in men with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.
September 15, 2011: German scientists are developing a microchip sensor that can be implanted near a prostate cancer tumor to monitor its growth aggressiveness, by sensing when oxygen levels in surrounding tissue drop.
September 13, 2011: ZYTIGA® (abiraterone acetate), a once-daily, oral androgen biosynthesis inhibitor is a new prostate cancer treatment that has been approved for use by the European Commission.
August 25, 2011: The FDA has granted Fast Track designation for the investigational drug Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer in patients whose cancer has spread to the bone (bone metastasis).
July 26, 2011: Janssen-Cilag International NV has announced that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of ZYTIGA® (abiraterone acetate) under an accelerated regulatory review procedure. ZYTIGA is a once-daily, oral, androgen biosynthesis inhibitor developed for the treatment of prostate cancer.
June 23, 2011: Investigators at the Mayo Clinic, with collaborators in the United Kingdom, say they have cured prostate tumors in mice with an experimental human vaccine that had no apparent side effects.
June 7, 2011: OncoGenex Pharmaceuticals, Inc. announces new data showing how its lead investigational compound, custirsen (OGX-011/TV-1011), may work with innovative therapies MDV3100 and heat-shock protein 90 (Hsp90) inhibitors to suppress prostate cancer cell survival and improve treatment outcomes.
May 2, 2011: The FDA has approved abiraterone acetate (Zytiga), a new prostate cancer treatment for late-stage, castration-resistant prostate cancer as a combination therapy with prednisone in patients who have received prior chemotherapy with docetaxel.
April 19, 2011: BioSante Pharmaceuticals, Inc. announced that it has licensed its prostate cancer vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).
February 15, 2011: The nation's first FDA-approved cancer treatment vaccine, Provenge (sipuleucel-T), is being offered for the first time in Western New York at Roswell Park Cancer Institute.
February 3, 2011: The FDA reports it will not approve an indication for the benign prostatic hyperplasia (BPH) drug dutasteride (Avodart) for use in prostate cancer prevention. GlaxoSmithKline applied to have the drug approved for use in patients with high prostate-specific antigen levels, but who did not have prostate cancer in a biopsy.
December 9, 2010: An FDA advisory panel has voted overwhelmingly that GlaxoSmithKline's dutasteride (Avodart) and Merck's finasteride (Proscar) should not be used to prevent prostate cancer because the drugs are linked to a higher incidence of high-grade tumors.
October 5, 2010: Two new prostate cancer treatments for castration-resistant prostate cancer have been approved the the FDA. Sipuleucel-T (brand name Provenge; from Dendreon) is the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (brand name Jevtana; from Sanofi-Aventis) is approved for second-line treatment of metastatic castration-resistant prostate cancer in men who were previously treated with the chemotherapy drug docetaxel (brand name Taxotere; from Sanofi-Aventis).
August 16, 2010: BioProtect's SpaceGuard Balloon is a new device for men with prostate cancer who are undergoing radiotherapy treatments. This implant separates the prostate from healthy tissues and organs surrounding the prostate to minimize the radiation that is delivered to these organs. The implant then dissolves after 3-6 months. A multi-center clinical trial is underway in the US, Europe and Israel.
August 11, 2010: Augmenix, Inc. announces the first commercial implantation of the company's SpaceOAR System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues.
April 29, 2010: Dendreon Corporation announced that the U.S. Food and Drug Administration has approved their drug Provenge (sipuleucel-T) as a new prostate cancer treatment for asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
February 17, 2010: A very small clinical study (29 men) conducted by researchers at Queen's University suggests that a very low dose of nitroglycerin may slow and even halt the progression of prostate cancer. While larger studies are needed, this is a very interesting new prostate cancer treatment.
Discuss information from this website with a medical professional